Miért ugrik az SLS részvény az előpiacon: a SELLAS Life Sciences újraindítja a REGAL 3. fázisú visszaszámlálást
SELLAS Life Sciences rose 3.4% to $4.29 in premarket trading Monday after closing at $4.15 Friday on heavy volume. Traders are watching for results from its phase 3 AML trial, with final survival data expected by mid-March. Short interest stands at 41.3 million shares, about 24% of float. SELLAS reported $71.8 million in cash at year-end.